Boule Diagnostics

Interim Report
Q1 2022

Financial Highlights

NET SALES, MSEK
132.5
GROSS MARGIN
42.9
%
OPERATING PROFIT, MSEK
10.3
OPERATIONAL CASH FLOW, MSEK
-1.3
Jesper

Strong growth in sales and improved operating profit

Boule started the year with strong growth in sales. We recorded our highest net sales for a first quarter, just below the record net sales in fourth quarter 2021. OEM business with consumables for other manufacturers is continuing to develop positively and reached a new level. Although some markets, particularly in South East Asia, are continuing to be impacted by the pandemic, net sales in Asia doubled in comparison with the previous year.

CEO COMMENTS

Net sales by region

Net sales by product

Near-patient diagnostics

Complete Blood Count (CBC) is the most common test for in vitro diagnostics. In 2019, the decentralized and patient-related hematology segment had an estimated market value of just over SEK 6 billion, while the corresponding segment for the veterinary market was valued at approximately SEK 2.6 billion

Map En

100
+

Countries

SEK
9
BILLION

Human and veterinary market

140
MILLION

Tests per year

TO THE REPORT

ABOUT BOULE DIAGNOSTICS

Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies.